Ibrutinib for mantle cell lymphoma.
Plymouth, United Kingdom. In Future Oncol, Feb 2016
Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase which acts by downstream inhibition of the B-cell receptor.
Mantle Cell Lymphoma.
Australia. In J Clin Oncol, Feb 2016
In particular, agents recently approved by the Food and Drug Administration include the proteasome inhibitor bortezomib, immunomodulator lenalidomide, and Bruton's tyrosine kinase inhibitor ibrutinib.
Chronic lymphocytic leukemia (CLL) - Then and Now.
Houston, United States. In Am J Hematol, Jan 2016
In therapy, the field of CLL has seen major changes from oral chlorambucil and steroids prior to 1980s, to chemo-immunotherapy (CIT) with fludarabine, cyclophosphamide, rituximab (FCR) to the orally administered targeted therapeutic agents inhibiting kinases in the B cell receptor (BCR) signaling pathway such as Ibrutinib (BTK inhibitor) and Idelalisib (p110 PI3Kδ inhibitor) and novel anti-CD20 mAb's (monoclonal antibodies) such as obinutuzumab.
Covalent targeting of acquired cysteines in cancer.
Utrecht, Netherlands. In Curr Opin Chem Biol, Dec 2015
For example, targeting cysteine residues in the ATP-binding pockets of kinases with thiol-reactive molecules has afforded increased selectivity and potency to drugs like imbrutinib, which inhibits the oncogene BTK, and CO-1686 and AZD9291 that target oncogenic mutant EGFR.